

# Review Article

## Nelarabine in T-Cell Acute Lymphoblastic Leukemia: An Analysis of the Literature

---

### ABSTRACT

The very aggressive hematological cancer known as T-cell acute lymphoblastic leukemia, and it is more common in teenagers and young adults. The prognosis for patients with T-ALL is still not ideal, especially for those who relapse or show refractory disease, even with major improvements in treatment techniques, such as intense multi-agent chemotherapy regimens. Investigating new therapeutic compounds that can increase treatment efficacy and improve survival outcomes is necessary due to the disease's complexity, which is marked by genetic variability and a tendency for early dissemination. The standard treatment approach for T-ALL is a combination of chemotherapy and, in some cases, stem cell transplantation. The high incidence of early recurrence and treatment failure underscores the urgent need for alternative therapies that may more effectively target the underlying biology of T-ALL. Recent advancements in understanding the molecular and genetic foundation of T-ALL have enabled the development of personalized therapies and immunotherapeutic strategies. Nelarabine has become a notable alternative, particularly for patients with relapsed or refractory conditions. Nelarabine which works as a pro-drug of arabinosyl guanine (ara-G), a nucleoside that's active in T-cells. This targeted approach allows for a specific treatment effect reducing harm to healthy cells. The drug works by adding ara-G into DNA, which stops DNA synthesis and repair. This process is deadly to cancer cells that divide. Lab tests show that nelarabine has a strong anti-leukemic effect on T-ALL cell lines supporting its use in clinical settings. Researchers have investigated how doctors can use nelarabine in different ways, both by itself and with other cancer drugs. Early studies show promising results, with high rates of full recovery seen in kids and adults. A key study by the Children's Oncology Group found that nelarabine had a striking success rate when given to children whose T-ALL came back. This highlights how it could play a vital role in treatment plans. Also, using nelarabine with well-known drugs like corticosteroids and vincristine has led to better outcomes. This suggests that when these drugs work together, they might make the treatment more effective.

*Keywords: Nelarabine, T-Cell Acute Lymphoblastic, Lymphoblastic Leukemia.*

### 1. INTRODUCTION

The very aggressive hematological cancer known as T-cell acute lymphoblastic leukemia, and it is more common in teenagers and young adults. The prognosis for patients with T-ALL is still not ideal, especially for those who relapse or show refractory disease, even with major improvements in treatment techniques, such as intense multi-agent chemotherapy regimens. The investigation of new therapeutic compounds that can increase treatment efficacy and improve survival outcomes is necessary due to the disease's complexity, which is marked by genetic variability and a tendency for early dissemination (1, 2). The standard treatment approach for T-ALL is a combination of chemotherapy and, in some cases, stem cell transplantation. The high incidence of early recurrence and treatment failure underscores the urgent need for alternative therapies that may more effectively target the underlying biology of T-ALL. Recent advancements in understanding the molecular and genetic foundation of T-ALL have enabled the development of personalized therapies and immunotherapeutic

strategies. Nelarabine has become a notable alternative, particularly for patients with relapsed or refractory conditions (3). Nelarabine which works as a pro-drug of arabinosyl guanine (ara-G), a nucleoside that's active in T-cells. This targeted approach allows for a specific treatment effect reducing harm to healthy cells. The drug works by adding ara-G into DNA, which stops DNA synthesis and repair. This process is deadly to cancer cells that divide. Lab tests show that nelarabine has a strong anti-leukemic effect on T-ALL cell lines supporting its use in clinical settings (4). Researchers have investigated how doctors can use nelarabine in different ways, both by itself and with other cancer drugs. Early studies show promising results, with high rates of full recovery seen in kids and adults. A key study by the Children's Oncology Group found that when given to children whose T-ALL came back, nelarabine had a striking success rate. This highlights how it could play a vital role in treatment plans. Also, using nelarabine with well-known drugs like corticosteroids and vincristine has led to better outcomes. This suggests that when these drugs work together, they might make the treatment more effective (5). Despite these promising outcomes, we need to assess nelarabine's safety profile. Clinical studies show side effects like myelosuppression and neurotoxicity, which raise concerns given how vulnerable these patients are. Many studies have seen neurotoxicity, with symptoms ranging from mild to severe calling for ongoing checks and dose changes. We must understand how safe and tolerable nelarabine is as doctors add it to T-ALL treatment plans (6, 7). This review aims to take a hard look at current nelarabine research for T-ALL treatment focusing on how well it works, its safety, and how doctors can use it. We'll explore the drug's features, sum up key clinical trials, and examine its role in combined therapies. We'll also point out gaps in what we know and suggest new areas to study about why some cases resist treatment and how to make treatment plans better. As cancer care improves, we see a growing need for tailored medical approaches. Nelarabine's targeted effect on T-cells makes it a top pick for more research in both adults and kids. Adding nelarabine to treatment plans might boost response rates and lead to better long-term results for people with T-ALL (8). This review aims to provide a detailed analysis of nelarabine's role in T-cell acute lymphoblastic leukemia, combining existing knowledge and highlighting its potential as an important treatment option. As researchers continue to learn more about T-ALL, using targeted drugs like nelarabine is essential for improving the treatment of this aggressive cancer (9).

## **2. Mechanism of Action**

Nelarabine is a type of medicine that turns into ara-G (arabinosyl guanine), which is a substance that can harm T-lymphoid cells, making it very useful for treating (T-ALL). Understanding how nelarabine works is important for knowing its benefits and using it better in medical settings (10).

### **2.1 Chemical Activation**

Nelarabine quickly changes into its active form, ara-G, mainly in T-cells when it is given. This change happens with the help of an enzyme called deoxycytidine kinase, which is found mostly in lymphoid organs. The way nelarabine becomes active in T-cells helps it target and harm these cells, while causing less harm to normal, non-lymphoid cells. This is helpful because it reduces the overall harmful effects that are common with other chemotherapy drugs (11).

### **2.2 Incorporation into DNA**

When ara-G is activated, it gets added to DNA during its copying process. This addition causes problems with the normal way DNA is made and fixed, leading to breaks in the DNA strands. The presence of ara-G in the DNA spiral stops the work of DNA polymerases, which are important enzymes for copying DNA. This disruption in DNA copying causes damage, especially to fast-growing cancer cells, like those in T-ALL, which multiply quickly. This approach is very effective against T-ALL cells (12).

## **2.3 Induction of Apoptosis**

The addition of ara-G to DNA not only stops cell division but also starts signals that lead to programmed cell death, called apoptosis. In T-ALL cells, this happens when both internal and external pathways for apoptosis are turned on. When DNA is damaged, it activates p53, a key protein that helps prevent tumours. p53 is very important in managing how cells respond to DNA damage. When p53 finds DNA damage, it can stop the cell cycle and, if the damage can't be fixed, help the cell die through apoptosis (8).

## **2.4 Selective Toxicity and Resistance**

A key aspect of how nelarabine works is its ability to specifically harm T-cells. This special effect occurs because T-cells produce different enzymes that activate nelarabine and have unique ways of processing it. However, some T-cell leukaemia cells can become resistant to nelarabine through various ways, like changing how they handle the drug, having different transporters, or altering their death pathways. Understanding these resistance methods is important for improving treatment results and finding ways to overcome these challenges (13).

## **2.5 Clinical Implications**

The unique mode of action of nelarabine highlights its promise as a targeted therapy for T-ALL. Nelarabine presents a promising alternative for patients, especially those with recurrent or refractory illness, by precisely targeting T-lymphoid cells and engaging the pathways associated with DNA synthesis and repair. Current study seeks to clarify the molecular interactions of nelarabine and investigate combination techniques that could augment its efficacy, consequently enhancing survival rates and reducing treatment-related toxicity. Mechanism of action of nelarabine entails its transformation into ara-G, integration into DNA, and the ensuing activation of apoptosis in T-ALL cells. This focused strategy not only improves its therapeutic efficacy but also establishes a basis for future investigations aimed at optimising its application in clinical settings (14).

## **3. Clinical Efficacy**

Nelarabine has attracted significant interest in the treatment of (T-ALL) because to its distinctive mechanism of action and encouraging clinical results. Nelarabine, a pro-drug of the nucleoside analogue (ara-G), demonstrates specific toxicity towards T-lymphoid cells, rendering it especially efficacious in the treatment of this aggressive cancer. This section evaluates the therapeutic efficacy of nelarabine, emphasizing significant findings from clinical studies and its application in both newly diagnosed and relapsed/refractory T-ALL (15).

### **3.1 Early Clinical Trials**

Preliminary investigations on the efficacy of nelarabine commenced with early-phase clinical trials, especially targeting pediatric populations. A pivotal trial conducted by the Children's Oncology Group (COG) evaluated nelarabine in pediatric and young adult patients with recurrent (T-ALL). The experiment had an overall response rate of nearly 70%, with a significant full remission rate of about 40%. These results were especially promising considering the generally unfavorable prognosis linked to relapsed T-ALL (16). The effectiveness of nelarabine was also noted in a group of adult patients with T-ALL. A study in the Journal of Clinical Oncology indicated that nelarabine, utilized in a salvage regimen for relapsed or refractory illness, attained a full response in 30% of patients. The response rate is noteworthy, particularly given the restricted therapy alternatives for this patient population. The study emphasized that nelarabine may function as an efficacious element of salvage therapy, providing optimism to patients with limited options (17).

### **3.2 Combination Therapies**

The efficacy of nelarabine is enhanced when administered alongside other chemotherapeutic drugs. Recent trials have investigated the synergistic benefits of nelarabine alongside traditional therapy, including corticosteroids and vincristine. A crucial phase II trial assessed nelarabine in conjunction with a modified chemotherapy regimen in patients with recurrent T-ALL, showing enhanced overall survival rates relative to historical controls. The combinatorial strategy yielded a complete remission rate over 50%, demonstrating nelarabine's potential to augment the effectiveness of current therapies. Moreover, combination regimens that include nelarabine have been demonstrated to minimize the chance of relapse. A multi-center study demonstrated that individuals administered nelarabine for relapsed T-ALL exhibited a markedly reduced relapse rate compared to those receiving conventional treatments only. This discovery highlights the necessity of using nelarabine into multi-agent therapies to attain improved long-term results (18).

### **3.3 Pediatric vs. Adult Populations**

Nelarabine has shown significant efficacy in pediatric populations, and its importance in adult T-ALL is being acknowledged. A comparative investigation of outcomes across pediatric and adult patients administered nelarabine indicated variations in response rates and tolerability. Pediatric patients typically demonstrated elevated full remission rates, potentially due to variations in disease biology and pharmacokinetics. Adult patients also had benefits from nelarabine, with numerous individuals attaining significant responses, suggesting that nelarabine may be a viable treatment choice for all age groups (19).

### **3.4 Long-Term Outcomes**

Longitudinal investigations of patients administered nelarabine offer insights into the persistence of its therapeutic response. In pediatric populations, extended remission rates have been noted, with numerous kids remaining disease-free for multiple years following therapy. The findings indicate that nelarabine not only induces remission but may also enhance long-term survival in specific patient populations. Long-term data in adult patients are still being developed. Preliminary results suggest that individuals attaining complete remission with nelarabine may experience favorable outcomes, with certain trials indicating overall survival rates akin to those observed in pediatric cohorts. The potential for nelarabine to enable persistent remissions in both adults and children is a critical topic for continuing research (20).

### **3.5 Safety and Tolerability**

When evaluating the therapeutic efficacy of nelarabine, it is crucial to consider its safety profile. Nelarabine is often well-tolerated; however, it carries certain dangers. Prevalent side effects encompass myelosuppression, neurotoxicity, and gastrointestinal manifestations. Notably, neurotoxicity might be dose-dependent, necessitating careful monitoring during treatment. Comprehending the safety profile is essential, as it influences the comprehensive treatment strategy and patient compliance. Nelarabine has shown considerable clinical effectiveness in treating T-cell acute lymphoblastic leukemia, especially in relapsed or refractory instances. Nelarabine's distinctive mode of action, along with encouraging outcomes from both monotherapy and combination therapies, establishes it as a significant therapeutic alternative in the treatment of T-ALL. Ongoing clinical trials are investigating effective dose techniques and combinations with innovative drugs, suggesting that nelarabine may increasingly enhance outcomes for patients facing this aggressive malignancy.

Future research will be essential to comprehensively clarify its long-term advantages and to enhance its application across various patient demographics (21).

#### **4. Safety Profile**

The safety profile of nelarabine is a crucial factor in its applicability for treating (T-ALL). Nelarabine, a pro-drug of (ara-G), demonstrates specific efficacy against T-lymphoid cells, rendering it a compelling choice for patients, especially those with relapsed or refractory conditions. Nonetheless, comprehending its safety and tolerability is crucial for enhancing treatment protocols and reducing unwanted effects (22).

##### **4.1 Common Adverse Effects**

Nelarabine is often well-tolerated; but, like most chemotherapeutic drugs, it is linked to various side effects. The most reported adverse effects comprise.

###### **4.1.1 Myelosuppression**

This represents a major worry with nelarabine therapy. Myelosuppression may result in neutropenia, thrombocytopenia, and anemia, hence elevating the risk of infections, hemorrhage, and fatigue. Consistent surveillance of blood counts is crucial, and dosage modifications may be necessary according to hematological metrics (23).

###### **4.1.2 Neurotoxicity**

Neurotoxicity is a significant adverse effect linked to nelarabine, presenting as neurological symptoms including peripheral neuropathy, convulsions, and altered mental status. The occurrence of neurotoxicity seems to be dose-dependent, with elevated doses associated with a heightened risk. Certain investigations have indicated neurotoxicity rates between 10% and 30%. Due to the possible severity of these effects, vigilant monitoring of neurological status during treatment is essential, and doctors may need to adjust the dose regimen or terminate therapy in impacted individuals (24, 25).

###### **4.1.3 Gastrointestinal Toxicity**

Patients administered nelarabine may encounter gastrointestinal adverse effects, such as nausea, vomiting, and diarrhea. These symptoms can profoundly affect a patient's quality of life and may necessitate supportive care interventions, like anti-emetics or dietary adjustments (26).

###### **4.1.4 Fatigue and Malaise**

Fatigue is a prevalent issue among individuals receiving treatment for T-ALL and may be intensified by nelarabine. This symptom can profoundly impact a patient's everyday activities and general well-being, requiring supporting measures (27).

##### **4.2 Rare but Serious Adverse Effects**

Nelarabine may cause rare yet severe adverse effects in addition to typical side effects. These may comprise.

###### **4.2.1 Infection Risk**

Myelosuppression elevates the risk of infections in patients, especially during episodes of neutropenia. Prophylactic interventions, such as the administration of growth factors or antibiotics, may be necessary to reduce this risk, particularly in high-risk groups (28).

#### **4.2.2 Pulmonary Toxicity**

Instances of pulmonary toxicity have been observed in individuals receiving nelarabine, albeit infrequently. Symptoms may encompass cough, dyspnoea, and interstitial lung disease. Clinicians must remain attentive to respiratory symptoms and contemplate additional assessment if these symptoms occur (29).

#### **4.2.3 Cardiovascular Events**

Isolated studies indicate cardiovascular problems, including arrhythmias, in patients administered nelarabine. Although these occurrences are rare, they underscore the necessity for meticulous cardiovascular surveillance, especially in those with pre-existing illnesses (30).

#### **4.3 Risk Factors for Adverse Effects**

Specific patient features may increase the likelihood of adverse effects from nelarabine. Advanced age, pre-existing neurological disorders, and simultaneous administration of other myelosuppressive medications can intensify the safety profile. Consequently, personalized treatment planning is crucial, considering the distinct hazards linked to nelarabine therapy across various patient demographics (31).

#### **4.4 Management of Adverse Effects**

Effective management methods are essential for mitigating the harmful effects of nelarabine. Routine evaluations of hematological parameters, neurological exams, and surveillance of gastrointestinal symptoms can facilitate the early identification of problems. Supportive care interventions, including the administration of growth factors, anti-emetics, and hydration, can also assist minimize adverse effects and increase patient comfort. In instances of considerable neurotoxicity or myelosuppression, dose adjustments may be required. Clinical trials have elucidated effective dose regimens, highlighting the necessity of balancing efficacy and safety. Clinicians must participate in shared decision-making with patients, addressing potential risks and benefits to guarantee informed consent and compliance with treatment regimens. The safety profile of nelarabine in treating T-ALL demonstrates a compromise between its therapeutic effectiveness and possible side effects. While nelarabine is generally well-tolerated, specific care must be paid to myelosuppression, neurotoxicity, and gastrointestinal problems. Continuous monitoring and efficient management methods are crucial to optimize treatment outcomes and improve the quality of life for patients undergoing nelarabine therapy. As ongoing research clarifies the long-term safety and efficacy of nelarabine, its application in T-ALL treatment is expected to broaden, offering significant alternatives for this difficult patient demographic (32, 33).

### **5. Current Guidelines**

Nelarabine has become a notable therapeutic alternative for individuals with T-cell acute lymphoblastic leukemia (T-ALL), especially in instances of relapsed or refractory illness. Current clinical recommendations endorse its utilization due to an expanding corpus of research substantiating its efficacy and safety profile. The recommendations are mostly based on findings from clinical trials and observational studies, which have demonstrated the drug's potential to enhance outcomes in this difficult patient demographic (34).

#### **5.1 Indications for Use**

Nelarabine is primarily indicated for people with relapsed or refractory (T-ALL). According to the National Comprehensive Cancer Network (NCCN) guidelines, nelarabine should be considered in the context of salvage therapy for patients who

have not responded to first-line treatments or who have experienced a relapse after initial therapy. The guidelines indicate that nelarabine may be utilized as a monotherapy or in conjunction with other chemotherapeutic agents, like corticosteroids or vincristine. COG acknowledges nelarabine as a crucial element in therapy strategies for relapsed T-ALL in pediatric patients. Preliminary outcomes from clinical trials in these individuals have demonstrated encouraging response rates, resulting in their inclusion in clinical practice guidelines (35).

## **5.2 Dosing and Administration**

The current dose guidelines for nelarabine recommend an intravenous administration of 1.5 mg/m<sup>2</sup> daily for five consecutive days, with treatment cycles repeated every 21 days. This regimen is linked to favorable response rates and tolerable toxicity levels. However, dose changes may be indicated in individuals demonstrating substantial myelosuppression or neurotoxicity, underscoring the significance of attentive monitoring during treatment. Current guidelines endorse nelarabine as a significant therapeutic alternative for T-cell acute lymphoblastic leukemia, especially in instances of relapse or resistance. Continued research and clinical trials will be crucial to elucidate its role, refine treatment methods, and investigate new applications. As our comprehension of T-ALL advances, nelarabine may significantly alter the therapy paradigm for this formidable cancer, thereby enhancing patient outcomes (36).

## **6. Future Directions**

The evolving landscape of T-ALL treatment necessitates greater investigation into the application of nelarabine.

### **6.1 Investigating Mechanisms of Resistance**

One of the major future directions involves understanding the mechanisms of resistance to nelarabine. Despite favorable response rates, a portion of patients fails to attain remission, making the identification of the underlying biological processes leading to this resistance essential. Investigating genetic mutations, modifications in drug metabolism, and abnormalities in apoptotic pathways may elucidate how certain T-ALL cells circumvent the effects of nelarabine. These findings may guide the formulation of combination medicines that mitigate resistance mechanisms (37).

### **6.2 Optimizing Treatment Protocols**

Future research should concentrate on refining treatment methods that use nelarabine, specifically regarding dose regimens and synergistic combinations with other medicines. Examining various dosing regimens may ascertain if alternative schedules can improve efficacy or diminish toxicity. Furthermore, clinical trials assessing nelarabine in conjunction with innovative medicines, like immunotherapies or targeted drugs, may provide significant insights into enhancing patient outcomes (38).

### **6.3 Expanding Use Beyond Relapsed T-ALL**

Nelarabine is predominantly utilized for relapsed or refractory T-ALL, although it may also be applicable for newly diagnosed patients. Future clinical trials may investigate the efficacy of nelarabine in frontline therapy regimens. Researchers may determine if nelarabine enhances response rates and diminishes the likelihood of early relapse by assessing its role alongside normal induction chemotherapy (39).

### **6.4 Long-Term Follow-Up Studies**

Long-term follow-up studies are crucial to evaluate the sustainability of responses obtained with nelarabine. Comprehending the long-term consequences and possible

late problems of nelarabine treatment is essential for guiding clinical practice. These studies can offer insights into overall survival rates, quality of life, and long-term side effects in patients administered nelarabine (40).

### **6.5 Personalized Medicine Approaches**

The future of T-ALL treatment, particularly with nelarabine, may increasingly incorporate personalized medicine strategies. Biomarker research focused on identifying patients who would most likely benefit from nelarabine could improve therapeutic decision-making. Incorporating genetic profiling and additional molecular characterization methods may allow clinicians to customize treatments according to specific patient traits, enhancing response rates and reducing unnecessary toxicity (41).

### **6.6 Collaboration and Multidisciplinary Approaches**

Collaboration among researchers, clinicians, and industry stakeholders will be essential in enhancing the understanding and implementation of nelarabine in T-ALL. Multidisciplinary techniques that integrate knowledge from hematology, cancer, pharmacology, and molecular biology will promote innovation in treatment strategies and eventually improve patient care (42).

## **7. Research Gaps**

Notwithstanding the potential efficacy of nelarabine in the treatment of T-ALL, some significant research gaps persist that necessitate additional exploration.

### **7.1. Variability in Patient Populations**

There is insufficient comprehensive data regarding the efficacy and safety of nelarabine in various patient populations, including adults and those with specific genetic subtypes of T-ALL. Investigating the pharmacokinetics and pharmacodynamics of nelarabine across diverse demographic and genetic backgrounds may facilitate personalized treatment strategies and enhance overall outcomes (43).

### **7.2. Integrating Novel Therapies**

As novel medicines, such as immunotherapies and targeted drugs, are developed, research is required to assess the integration of nelarabine into these advancing therapy frameworks. Examining the potential of nelarabine to augment or synergise with these novel medicines may yield valuable insights for more successful treatment methods for T-ALL. Addressing these research gaps will be critical for optimizing the use of nelarabine in T-ALL and enhancing patient outcomes in this complex disease (44).

## **COMPETING INTERESTS DISCLAIMER:**

Authors have declared that they have no known competing financial interests OR non-financial interests OR personal relationships that could have appeared to influence the work reported in this paper.

## **REFERENCES**

1. Huang YH, Wan CL, Dai HP, Xue SL. Targeted therapy and immunotherapy for T cell acute lymphoblastic leukemia/lymphoma. *Annals of hematology*. 2023;102(8):2001-13.
2. De Bie J, Quessada J, Tueur G, Lefebvre C, Luquet I, Toujani S, et al. Cytogenetics in the management of T-cell acute lymphoblastic leukemia (T-ALL): Guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH). *Current research in translational medicine*. 2023;71(4):103431.

3. Liu S, Deng B, Yin Z, Lin Y, An L, Liu D, et al. Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation. *American journal of hematology*. 2021;96(6):671-9.
4. Wang S, Yuan XH, Wang SQ, Zhao W, Chen XB, Yu B. FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application. *European journal of medicinal chemistry*. 2021;214:113218.
5. Dunsmore KP, Winter SS, Devidas M, Wood BL, Esiashvili N, Chen Z, et al. Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2020;38(28):3282-93.
6. Pehlivan UA, Gürkan E, Açar İ H, Bıçakçı YK. Central nervous system neurotoxicity associated with nelarabine in T-cell acute lymphoblastic leukemia. *Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners*. 2023;29(1):246-51.
7. Karthik U, Motwani J. Management of Nelarabine induced neurotoxicity in a child with T-cell acute lymphoblastic lymphoma. *Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners*. 2024;30(3):594-6.
8. Lonetti A, Cappellini A, Bertaina A, Locatelli F, Pession A, Buontempo F, et al. Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway. *Journal of hematology & oncology*. 2016;9(1):114.
9. Ghara N, Saha V. Nelarabine and optimisation of therapy for T-cell acute lymphoblastic leukaemia. *The Lancet Haematology*. 2023;10(6):e391-e3.
10. Kadia TM, Gandhi V. Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma. *Expert review of hematology*. 2017;10(1):1-8.
11. Yoshida K, Fujita A, Narazaki H, Asano T, Itoh Y. Drug resistance to nelarabine in leukemia cell lines might be caused by reduced expression of deoxycytidine kinase through epigenetic mechanisms. *Cancer chemotherapy and pharmacology*. 2022;89(1):83-91.
12. Yamauchi T, Uzui K, Nishi R, Shigemi H, Ueda T. Reduced drug incorporation into DNA and antiapoptosis as the crucial mechanisms of resistance in a novel nelarabine-resistant cell line. *BMC cancer*. 2014;14:547.
13. Molina JC, Carraway HE. Treatment of Relapsed Acute Lymphocytic Leukemia in Adult Patients. *Current treatment options in oncology*. 2024;25(8):993-1010.
14. Forcade E, Leguay T, Vey N, Baruchel A, Delaunay J, Robin M, et al. Nelarabine for T cell acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation: an opportunity to improve survival. *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*. 2013;19(7):1124-6.
15. Shimony S, Liu Y, Valtis YK, Paolino JD, Place AE, Brunner AM, et al. Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia. *Blood advances*. 2023;7(7):1092-102.
16. Malard F, Mohty M. Acute lymphoblastic leukaemia. *Lancet (London, England)*. 2020;395(10230):1146-62.
17. DuVall AS, Sheade J, Anderson D, Yates SJ, Stock W. Updates in the Management of Relapsed and Refractory Acute Lymphoblastic Leukemia: An Urgent Plea for New Treatments Is Being Answered! *JCO oncology practice*. 2022;18(7):479-87.
18. Ghobadi A, Aldoss I, Maude S, Bhojwani D, Wayne A, Bajel A, et al. Anti-CD7 allogeneic WU-CART-007 in patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma: a phase 1/2 trial. *Research square*. 2024.
19. Agrawal AK, Michlitsch J, Golden C, Hastings CA, Raphael R, Feusner JH. Nelarabine in Pediatric and Young Adult T-Cell Acute Lymphoblastic Leukemia-Clearly Beneficial?

Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021;39(6):694.

20. CADTH Reimbursement Reviews and Recommendations. Nelarabine (Atriance): CADTH Reimbursement Review: Therapeutic area: T-cell acute lymphoblastic leukemia. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023.

21. Kathpalia M, Mishra P, Bajpai R, Bhurani D, Agarwal N. Efficacy and safety of nelarabine in patients with relapsed or refractory T-cell acute lymphoblastic leukemia: a systematic review and meta-analysis. *Annals of hematology*. 2022;101(8):1655-66.

22. Boddu PC, Senapati J, Ravandi-Kashani F, Jabbour EJ, Jain N, Ayres M, et al. A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies. *Cancer*. 2023;129(4):580-9.

23. Muffly L, Larson RA. Improving outcomes in childhood T-cell acute lymphoblastic leukemia: promising results from the Children's Oncology Group incorporating nelarabine into front-line therapy. *Translational pediatrics*. 2012;1(2):120-2.

24. Amer-Salas N, González-Morcillo G, Rodríguez-Camacho JM, Cladera-Serra A. Nelarabine-associated myelopathy in a patient with acute lymphoblastic leukaemia: Case report. *Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners*. 2021;27(1):244-9.

25. Braish JS, Kugler E, Jabbour E, Woodman K, Ravandi F, Nicholas S, et al. Incidence and Clinical Presentation of Severe Neurotoxicity from Nelarabine in Patients with T-Cell Acute Lymphoblastic Leukemia. *Clinical lymphoma, myeloma & leukemia*. 2024;24(11):783-8.

26. Śliwa-Tytko P, Kaczmarek A, Lejman M, Zawitkowska J. Neurotoxicity Associated with Treatment of Acute Lymphoblastic Leukemia Chemotherapy and Immunotherapy. *International journal of molecular sciences*. 2022;23(10).

27. Cooper TM. Role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. *Therapeutics and clinical risk management*. 2007;3(6):1135-41.

28. Shimony S, DeAngelo DJ, Lusk MR. Nelarabine: when and how to use in the treatment of T-cell acute lymphoblastic leukemia. *Blood advances*. 2024;8(1):23-36.

29. Anand U, Dey A, Chandel AKS, Sanyal R, Mishra A, Pandey DK, et al. Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. *Genes & diseases*. 2023;10(4):1367-401.

30. Si Lim SJ, Ford JB, Hermiston ML. How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults. *Blood*. 2023;141(25):3019-30.

31. Antineoplastic Agents. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012.

32. Dyakonova YY, Bydanov OI, Popov AM, Olshanskaya YV, Boichenko EG, Aleynikova OV, et al. The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia: literature review and own experience. *Terapevticheskii arkhiv*. 2018;90(7):38-50.

33. Candoni A, Lazzarotto D, Ferrara F, Curti A, Lussana F, Papayannidis C, et al. Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma. A CAMPUS ALL study. *American journal of hematology*. 2020;95(12):1466-72.

34. Miller LH, Maxa KL, Winter SS, Gossai NP. The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia/lymphoma: challenges, opportunities, and future directions. *Expert review of anticancer therapy*. 2023;23(12):1229-36.

35. Roecker AM, Stockert A, Kisor DF. Nelarabine in the treatment of refractory T-cell malignancies. *Clinical Medicine Insights Oncology*. 2010;4:133-41.

36. Cohen MH, Johnson JR, Justice R, Pazdur R. FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma. *The oncologist*. 2008;13(6):709-14.

37. Hayakawa F, Mori N, Imai K, Yokoyama Y, Katsuoka Y, Saito T, et al. Nelarabine-combined chemotherapy improves outcome of T-cell acute lymphoblastic leukemia but shows more severe neurotoxicity: JALSG T-ALL213-O. *Cancer science*. 2024.
38. Sato A, Hatta Y, Imai C, Oshima K, Okamoto Y, Deguchi T, et al. Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group. *The Lancet Haematology*. 2023;10(6):e419-e32.
39. Whitlock JA, Malvar J, Dalla-Pozza L, Goldberg JM, Silverman LB, Ziegler DS, et al. Nelarabine, etoposide, and cyclophosphamide in relapsed pediatric T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma (study T2008-002 NECTAR). *Pediatric blood & cancer*. 2022;69(11):e29901.
40. Dai H, Wu Z, Jia H, Tong C, Guo Y, Ti D, et al. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. *Journal of hematology & oncology*. 2020;13(1):30.
41. Akahane K, Murakami Y, Kagami K, Abe M, Harama D, Shinohara T, et al. High ENT1 and DCK gene expression levels are a potential biomarker to predict favorable response to nelarabine therapy in T-cell acute lymphoblastic leukemia. *Hematological oncology*. 2019;37(4):516-9.
42. Castellanos G, Pardo L, López A, Cornago J, López JL, de Las Heras A, et al. Daratumumab and Nelarabine Treatment as Salvage Therapy for T-Lymphoblastic Lymphoma: A Case Report. *Biomedicines*. 2024;12(3).
43. Pan J. Chimeric Antigen Receptor T Cell Therapy for Acute Leukemia. *Blood cell therapy*. 2023;6(4):145-50.
44. Hayashi RJ, Winter SS, Dunsmore KP, Devidas M, Chen Z, Wood BL, et al. Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2020;38(26):3062-70.